Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients by 諛뺤쑀�옉
86
ABSTRACT
Purpose: Discontinuation of hormone therapy is known to lead to a poorer prognosis in 
breast cancer patients. We aimed to investigate the prescription gap as a prompt index of 
medication adherence by using prescription data extracted from patient electronic medical 
records.
Methods: A total of 5,928 patients diagnosed with invasive, non-metastatic breast cancer, 
who underwent surgery from January 1, 1997 to December 31, 2009, were enrolled 
retrospectively. The prescription data for 4.5 years of hormonal treatment and breast cancer-
related events after treatment completion were analyzed. We examined the characteristics 
and prognoses of breast cancer in patients with and without a 4-week gap.
Results: Patients with a gap showed a significantly higher risk of breast cancer recurrence, 
distant metastasis, breast cancer-specific death, and overall death after adjustment (hazard 
ratio [HR], 1.389; 95% confidence interval [CI], 1.089–1.772; HR, 1.568; 95% CI, 1.158–2.123; 
HR, 2.108; 95% CI, 1.298–3.423; and HR, 2.102; 95% CI, 1.456–3.034, respectively). When 
patients were categorized based on gap summation, the lower third (160 days) and fourth 
(391 days) quartiles showed a significantly higher risk of distant metastasis (HR, 1.758; 95% 
CI, 1.186–2.606 and HR, 1.844; 95% CI, 1.262–2.693, respectively).
Conclusion: A gap of > 4 weeks in hormonal treatment has negative effects on breast cancer 
prognosis, and can hence be used as a sentinel index of higher risk due to treatment non-
adherence. Further evaluation is needed to determine whether the gap can be used as a 
universal index for monitoring the adherence to hormonal treatment.
Keywords: Breast neoplasms; Estrogen antagonists; Medication adherence;  
Neoplasm metastasis
INTRODUCTION
Anti-estrogen hormone therapy is a major treatment modality in breast cancer, and long-
term results from randomized clinical trials have indicated its efficacy in reducing mortality 
rates of estrogen receptor-positive and progesterone receptor-positive breast cancer [1-4]. 
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Oral anti-estrogen agents are generally prescribed for 5 years, and have been used as the 
first-line adjuvant treatment for early hormone receptor-positive breast cancer. Although 
numerous resources and consistent efforts have been applied towards novel drug discovery, 
there has been no paradigm shift in the hormonal treatment of hormone receptor-positive 
breast cancer. Moreover, several studies have validated the benefits of extended hormonal 
treatment (for > 5 years) [3,5,6], and the number of recipients of long-term oral hormonal 
treatment has been increasing.
Adverse events due to hormonal treatment, such as hot flashes, arthralgia, or mood changes, 
increase the difficulty of medication adherence [7-10]. The socio-economic status of patients, 
including personal plans for marriage or childbirth, can also affect treatment compliance 
[11-15]. As adherence to hormonal treatment correlates strongly with breast cancer prognosis 
[8,16-19], treatment non-adherence, assessed by various methods, has been an important 
subject of previous research.
Though several studies have assessed the relationship between treatment discontinuation 
and breast cancer prognosis [19,20], there is a difference in the observations between 
controlled studies and actual clinical situations “Hawthorne effect”. Moreover, there 
may be a loss of information when estimating adherence based on claims data obtained 
from patients [21]. Nevertheless, data on patient visits and drug prescriptions being 
accumulated in electronic medical records (EMRs) closely mirror actual clinical data, and 
can thus facilitate compliance assessment. In particular, the prescription refill gap—an 
indicator of medication adherence—can be measured concurrently, as prescription data are 
accumulated [22].
In the present study, we aimed to examine differences in clinical outcomes according to 
the hormone prescription gap in breast cancer patients. To evaluate patient risk as a result 
of the gap in medication, we assessed prescription data extracted from EMRs in relation to 
outcomes in a breast cancer patient series. Moreover, we determined the suitability of using 
the prescription refill gap as an indicator of hormonal treatment adherence.
METHODS
In this retrospective study, we investigated the association between the gap in hormone 
treatment and breast cancer outcomes using clinical data from the Asan Medical Center. 
All clinical data were anonymized for research purposes using a de-identified clinical 
data warehouse: Asan BiomedicaL research Environment [23]. We assessed adherence by 
analyzing the gap between successive prescription refill dispensation visits, compared to 
the interval between regular visits or when the patient visited the hospital after a greater 
delay than expected. We examined the effect of adherence within the conventional treatment 
period (4.5 years) on the prognosis of breast cancer after that period.
Study design and subjects
We enrolled patients with pathologically confirmed stage I–III breast cancer who underwent 
surgery at Asan Medical Center between January 1, 1997, and December 31, 2009. Follow-
up data were collected up to May 31, 2015. Among the 10,426 breast cancer patients who 
underwent surgery at Asan Medical Center, we excluded those who met the following criteria: 
hormone receptor-negative cancer and/or no record of hormonal agent prescription and 
87https://ejbc.kr https://doi.org/10.4048/jbc.2019.22.e14
Prescription Gap and Late Breast Cancer Recurrence
presence of early recurrence and/or early loss to follow-up (within 4.5 years [54 months] after 
surgery). Figure 1 details the patient selection process.
Prescription data (prescription visit date and prescription duration) for hormonal 
treatments, including first-line adjuvant anti-estrogen oral medications (i.e., tamoxifen 
citrate, toremifene citrate, letrozole, anastrozole, and exemestane), were analyzed for each 
patient. Patient demographic data, including the age at breast cancer diagnosis, marital 
status at diagnosis, type of residential area, education level, body mass index, and family 
history of breast cancer, were additionally collected. Further, information on breast cancer 
stage, histologic type, histologic grade, operation methods, and adjuvant treatment (i.e., 
chemotherapy and/or radiation therapy) were included.
Determining the duration of the prescription refill gap
The number of days of treatment omission was estimated by subtracting the duration of 
medication coverage from the intervals between prescription dates. Prescription refill gaps 
(hereafter referred to as gaps) were recorded when the gap duration was > 4 weeks (28 days). 
The interval between routine follow-up and a prescription visit was 6 months, and the last 
visit (without prescription) was not included in the prescription data. Therefore, the total 
prescription period analyzed was 4.5 years (54 months), starting from the first prescription 
date; no cases of treatment extensions were considered. The gap was calculated up to 
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Breast cancer stage I–III, surgery at AMC
from January 1st 1997 to December 31st 2009
(n = 10,426)
With hormone receptor
negative breast cancer
(n = 3,031)
Without record of anti-estrogen
agent prescription in AMC
(n = 390)
Early follow-up loss
within 4.5 years
(n = 601)
Breast cancer recurrence
within 4.5 years
(n = 476)
Patients with hormone (estrogen/progesterone)
receptor positive breast cancer
(n = 7,395)
Patients who were prescribed anti-estrogen
oral medication
(n = 7,005)
Patients with follow-up more than 4.5 years
from the date of breast cancer surgery
(n = 6,404)
Patients without breast cancer recurrence up to
4.5 years from the date of breast cancer surgery
(n = 5,928)
Figure 1. Flow diagram of patient selection; a total of 5,928 patients were enrolled in this study. 
AMC = Asan Medical Center.
4.5 years after surgery (the duration of prescription completion). If the medication was 
discontinued within 4.5 years, the gap was estimated as the duration from the expected date 
of medication depletion to the date of prescription completion. The gap ranged from 29 to 
1,641 days (median gap: 92 days).
Outcome variables
We assessed the follow-up results for up to 10 years (120 months) from the date of 
prescription completion. As per a regular follow-up schedule, the last prescription visit was 
made 4.5 years after the first visit in the planned 5-year treatment regimen. Cancer-related 
outcome after treatment completion was evaluated after excluding cases of recurrence or 
death during the 4.5-year treatment period. The outcome parameters included breast cancer 
recurrence (of any type), distant metastasis, breast cancer-specific death, and overall death, 
which occurred after the 4.5-year treatment period.
Statistical analysis
All reported p values are 2-sided, and p-values < 0.05 were considered significant. Statistical 
analysis was performed using SPSS statistics version 21 (IBM Corp., Armonk, USA) and R 
version 3.2 (R Development Core Team, Vienna, Austria). Differences between groups were 
examined using the χ2 test for categorical variables. Survival curves were constructed using 
Kaplan-Meier estimates, and curves were compared using the log-rank test. To determine 
the accumulated effect of gaps, we sub-classified the patients with gaps according to 
the summation of the gap (gap sum). The gap-positive group was further divided into 4 
subgroups based on quartiles: from 1st quartile (patients with low gap sum) to 4th quartile 
(patients with high gap sum). The range of the gap sum was 29–1,625 days, and the cut-off 
between successive quartiles was 64, 160, and 391 days. Analysis using multivariate Cox 
proportional hazards regression model was performed according to the gap sum quartile. 
The relative risk of breast cancer outcomes was assessed to determine the linear tendency of 
increasing risk as the cumulated gap increased.
Ethics
This study was approved by the Institutional Review Board (IRB) of Asan Medical Center, 
Korea (IRB No. 2015-0924). The need for informed consent was waived by our Institutional 
Review Board, as this study involved routinely collected medical data that were anonymously 
managed at all stages, including during data cleaning and statistical analysis.
RESULTS
Patient characteristics
A total of 5,928 patients with no breast cancer recurrence within 4.5 years from the date of 
breast cancer surgery, were enrolled in the present study. Among these cases, 2,821 (47.6%) 
had a gap of > 4 weeks. The baseline demographic and clinical characteristics of patients 
with and without gaps are presented in Table 1. Patients who were younger (p < 0.001), had a 
non-married status at diagnosis (p < 0.001), had stage II breast cancer (p = 0.013), underwent 
mastectomy (p < 0.001), or did not undergo chemotherapy (p = 0.013) and/or radiation 
therapy (p < 0.001), were significantly more likely to have a gap. Patients with invasive 
lobular carcinoma tended to have a greater gap than patients with invasive ductal carcinoma, 
although this difference was not significant (p = 0.078).
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Prognostic and survival effect of the gap
Patients were followed up to 10 years from the completion of hormone treatment, and breast 
cancer recurrence (of any type) was observed in 318 patients in this period. Distant metastasis was 
noted in 214 patients and 116 breast cancer-related mortalities occurred. As shown in Figure 2, 
the presence or absence of the gap was found to be significantly linked to survival outcome in all 
breast cancer types. In patients with distant metastases, the survival estimate was 95% in patients 
without a gap, and 85% in patients with a gap (log rank, p < 0.001; Figure 2B).
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Table 1. Baseline characteristics of the enrolled patients, according to the presence of a gap
Characteristics Gap (−) (n=3,107, 52.4%) Gap (+)* (n=2,821, 47.6%) p-value†
Age at diagnosis (yr)
<40 423 (44.1) 536 (55.9) <0.001
40–49 1,509 (53.3) 1,324 (46.7) -
≥50 1,175 (55.0) 961 (45.0) -
Marital status at diagnosis
Unmarried 122 (39.2) 189 (60.8) <0.001
Married 2,969 (53.2) 2,613 (46.8) -
Residential area
Rural 812 (53.9) 695 (46.1) 0.193
Urban 2,288 (51.5) 2,117 (48.5) -
Education level
Low (≤Middle school graduation) 791 (51.3) 751 (48.7) 0.186
High (>Middle school graduation) 2,244 (53.3) 1,969 (46.7) -
BMI (kg/m2)
<25 2,277 (52.4) 2,067 (47.6) 0.990
≥25 830 (52.4) 754 (47.6) -
Family history of breast cancer
No 2,794 (52.0) 2,581 (48.0) 0.121
Yes 264 (55.7) 210 (44.3) -
Breast cancer stage
Stage I 1,391 (52.2) 1,272 (47.8) 0.013
Stage II 1,353 (51.4) 1,280 (48.6) -
Stage III 363 (57.4) 269 (42.6) -
Histology
Invasive ductal carcinoma 2,978 (52.2) 2,731 (47.8) 0.078
Invasive lobular carcinoma 112 (58.6) 79 (41.4) -
Histologic grade
Grade 1 288 (51.2) 275 (48.8) 0.171
Grade 2 1,977 (54.7) 1,635 (45.3) -
Grade 3 653 (52.6) 588 (47.4) -
Breast surgical method
Breast conserving surgery 1,727 (58.9) 1,207 (41.1) <0.001
Mastectomy 1,379 (46.2) 1,606 (53.8) -
Chemotherapy
No 1,289 (50.5) 1,262 (49.5) 0.013
Yes 1,803 (53.8) 1,549 (46.2) -
Radiation therapy
No 1,082 (44.1) 1,374 (55.9) <0.001
Yes 2,022 (58.5) 1,436 (41.5) -
BMI = body mass index.
*Gap (+): when the duration of treatment omission was more than 28 days; †p-value: t-test was used for age; for 
the other variables, the χ2 test was used. “Unknown” was treated as a missing value.
Accumulated prognostic effect of the gap
Multivariate Cox analysis indicated that the hazard ratio (HR) of distant metastasis was 
independently greater in patients with a gap (HR, 1.6; 95% confidence interval [CI], 1.182–
2.166), as compared to patients without a gap, after adjusting for age at diagnosis, breast 
cancer stage, chemotherapy, and radiation therapy. The risk of distant metastasis increased 
with an increase in the gap sum, although the increase was not significant in the first and 
second gap sum quartile groups (p = 0.250 and p = 0.200, respectively). However, in the third 
and fourth gap sum quartile groups, the risk of distant metastasis was significantly high (HR, 
1.758; 95% CI, 1.186–2.606 and HR, 1.844; 95% CI, 1.262–2.693; Table 2). The risk of distant 
metastasis constantly increased as the gap sum increased, and patients with a gap sum of 
approximately 3 years appeared to have a 50% greater risk of distant metastasis than those 
with lower gap sum values (Figure 3).
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Figure 2. Unadjusted Kaplan-Meier curves comparing patients with a gap and patients without a gap in terms of 4 possible outcomes of breast cancer: (A) 
Breast cancer recurrence (of any type), (B) Distant metastasis, (C) Breast cancer-specific death, and (D) Overall death.
DISCUSSION
In the present study, we assessed the prognostic significance of prescription gap and 
accumulated gap during hormonal treatment in a breast cancer cohort. Our findings 
indicate a negative effect of treatment omission on breast cancer prognosis, in agreement 
with previous studies that have correlated treatment adherence to better prognosis in breast 
cancer patients [8,16-18,24-26]. There are 2 important aspects of our study methodology 
which increase study reliability. Firstly, we used the prescription refill gap, including the non-
intended gap between visit intervals, as an indicator of adherence. The index for measuring 
medication adherence, such as medication possession ratio (MPR) (used in prior studies), 
can only indicate the ratio within a specific period after completing treatment. In contrast, 
the gap and gap sum values are more realistic and are immediate indicators of medication 
administration, as they can be measured using real-world data from EMRs. Secondly, 
we assessed the long-term follow up results—i.e., up to 10 years following treatment 
completion, or up to 14.5 years from treatment initiation. Hence, we excluded patients with 
early loss to follow-up and/or early recurrence of breast cancer, and thus, the prognostic 
significance of the period without hormonal treatment coverage was presented more 
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Table 2. Multivariate Cox regression analysis of the outcomes of breast cancer and covariates
Covariates Distant metastasis (n=214)
HR 95% CI p-value*
Gap
No gap 1
Gap (+) 1.6 1.182–2.166 0.002
Gap sum quartile (day)
No gap 1
1st quartile (≤64) 1.342 0.813–2.217 0.250
2nd quartile (65–160) 1.344 0.855–2.113 0.200
3rd quartile (161–391) 1.758 1.186–2.606 0.005
4th quartile (≥392) 1.844 1.262–2.693 0.002
BC = breast cancer; HR = hazard ratio; CI = confidence interval
*p-value was derived from multivariate Cox regression survival analysis adjusted by age at diagnosis, breast 
cancer stage, chemotherapy, and radiation therapy.
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Figure 3. RR of the gap sum for distant metastasis of breast cancer, adjusted by age at diagnosis, breast cancer 
stage, chemotherapy, and radiation therapy. 
RR = relative risk.
precisely. The prognostic value of disease characteristics (i.e., tumor size, grade, and node 
status) for early recurrence was thus minimized [27].
Hershman et al. [16] reported that an MPR of < 80% correlates with poor outcomes in breast 
cancer, and many other studies have defined poor adherence as an MPR < 80% [16,20,28]. 
Nevertheless, the gap may serve as a more prompt indicator for discrimination between 
groups with different breast cancer outcomes. We observed here that the difference in 
disease prognosis could be caused by the accumulation of non-intended treatment blanks. 
Our findings can be applied in the clinics to stratify patients according to days of treatment 
omission, and caution them about the risks of skipping or discontinuing medication,
The differences between study groups classified on the basis of a gap period cut-off of 4 
weeks were significant in terms of age, marital status, breast cancer stage, breast surgery 
methods, chemotherapy, and radiation therapy. Unmarried women tended to have a greater 
gap, which suggests that concerns regarding marriage and childbirth can affect compliance. 
However, as marital status was associated with the age at diagnosis (multicollinearity test, t = 
16.90; p < 0.001), we could not determine whether the origin of this association was marriage 
itself. A younger age at diagnosis was also found to correlate with the presence of a gap, 
which implies that the increased risk associated with younger age in breast cancer may be 
caused by poor adherence to hormonal treatment [29].
We further found from our present analysis that the breast cancer stage significantly differed 
based on the presence of the gap, although there was no marked linear tendency for this 
association. Our results showed that patients who received breast conserving surgery were 
more likely to adhere to hormonal treatment than those who received mastectomy (Table 1), 
in contrast to previous findings [20]. Patients receiving radiation and/or chemotherapy should 
visit the hospital during the early period of adjuvant treatment, as they would have a greater 
opportunity to communicate with clinicians. Since the emotional support of clinicians has 
positive effects on medication adherence of hormonal treatment [13,15], those patients would 
have higher chances of decreasing the gap. In patients who receive breast conserving surgery, 
the amount of remnant breast tissue and perceived risk of local recurrence can affect adherence. 
However, concerns regarding a bad prognosis should be evenly distributed as the gap does not 
only affect loco-regional recurrence but also distant metastasis.
Due to the limitation of the retrospective study, we did not investigate the actual cause of 
the treatment gap. In addition, there was no consideration of the cause of death associated 
with hormone therapy by analyzing overall death, and we could not determine from 
our present analyses whether skipping medication for 4 weeks would affect the clinical 
outcomes of breast cancer patients. The presence of < 3% treatment blank phases within 
the total treatment period is unlikely to be clinically relevant. Our current results are from a 
single center, and caution should be exercised about generalizing these findings, since the 
prescription pattern is unique to each medical center. Moreover, the issuing of a prescription 
does not always indicate an actual purchase or intake of medicine. Although these limitations 
should be considered, we contend from our present analysis that a gap of 4 weeks can be used 
as a validated surrogate index of adherence.
Hence, the gap can be used as a sentinel index for longer discontinuation and poor 
adherence. Moreover, the prescription gap is a convenient parameter that can be easily 
derived without the need for complicated equations, and ease of use implies that feedback 
93https://ejbc.kr https://doi.org/10.4048/jbc.2019.22.e14
Prescription Gap and Late Breast Cancer Recurrence
can be given to patients at each visit. Patient education and communication is regarded as 
the main modifiable factor in improving adherence [7,30], and a more prompt response from 
clinicians may be a good solution to alleviating gap issues. Further studies involving breast 
cancer patients at other medical centers, or alternatively involving other medications or 
diseases, would be useful. In addition, further evaluation would help determine whether the 
gap can be used as a universal index for monitoring the effectiveness of oral medication.
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